Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

ClinicalTrials.gov ID: NCT03640481

Public ClinicalTrials.gov record NCT03640481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy

Study identification

NCT ID
NCT03640481
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Kadmon, a Sanofi Company
Industry
Enrollment
159 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 10, 2018
Primary completion
Dec 10, 2023
Completion
Dec 10, 2023
Last update posted
Dec 11, 2024

2018 – 2023

United States locations

U.S. sites
35
U.S. states
22
U.S. cities
33
Facility City State ZIP Site status
Phoenix Childrens Hospital Site Number : 154 Phoenix Arizona 85016
University of Arizona - Cancer Center Site Number : 122 Tucson Arizona 85724
City of Hope Medical Center Site Number : 050 Duarte California 91010
University of California, Los Angeles (UCLA) - Medical Center Site Number : 104 Los Angeles California 90059
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center Site Number : 058 San Francisco California 94143
Stanford Cancer Center Site Number : 108 Stanford California 94305
Colorado Blood Cancer Institute Site Number : 098 Denver Colorado 80218
University of Miami - Sylvester Cancer Center Site Number : 097 Miami Florida 33136
Moffitt Site Number : 102 Tampa Florida 33612
Emory University School of Medicine Site Number : 100 Atlanta Georgia 30322
Augusta University Medical Center Site Number : 093 Augusta Georgia 30912
University of Illinois at Chicago Site Number : 139 Chicago Illinois 60612
University of Iowa Site Number : 126 Iowa City Iowa 52242
University of Kansas Cancer Center Site Number : 105 Fairway Kansas 66205
Center for Cancer Research National Cancer Institute Site Number : 107 Bethesda Maryland 20892-1203
Massachusetts General Hospital Site Number : 002 Boston Massachusetts 02114
Dana-Farber Cancer Institute Site Number : 004 Boston Massachusetts 02215
CS Mott Children's Hospital Site Number : 157 Ann Arbor Michigan 48109-5718
Barbara Ann Karmanos Cancer Institute-4100 John R St Site Number : 094 Detroit Michigan 48201
University of Minnesota Site Number : 051 Minneapolis Minnesota 55455
Washington University School of Medicine Site Number : 125 St Louis Missouri 63110
University of Rochester Site Number : 106 Rochester New York 14642
Wake Forest Site Number : 123 Winston-Salem North Carolina 27157
The Cleveland Clinic Foundation Site Number : 041 Cleveland Ohio 44195
James Cancer Hospital & Wexner Medical Center at the Ohio State University Comprehensive Cancer Center Site Number : 103 Columbus Ohio 43210
Oregon Health & Science University (OHSU) Site Number : 095 Portland Oregon 97239-3098
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132 Pittsburgh Pennsylvania 15232
Sarah Cannon and HCA Research Institute Site Number : 007 Nashville Tennessee 37203
Vanderbilt University Medical Center Site Number : 063 Nashville Tennessee 37232-6868
South Austin Medical Center Site Number : 091 Austin Texas 78704
MD Anderson Cancer Center Site Number : 057 Houston Texas 77030-4009
Texas Transplant Institute Site Number : 079 San Antonio Texas 78229
Fred Hutchinson Cancer Research Center Site Number : 052 Seattle Washington 98109
University of Wisconsin - Carbone Cancer Center Site Number : 135 Madison Wisconsin 53792
Froedtert Hospital and the Medical College of Wisconsin Site Number : 101 Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03640481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03640481 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →